Abstract
Present-day understanding of the architecture of the entire cell-wall of Mycobacterium tuberculosis amounts to a “core” template comprised of peptidoglycan with phosphodiester linkage, via a linker disaccharide, to a linear Dgalactofuran, to which, in turn, are attached several strands of a highly branched D-arabinofuran. The cell-wall mycolic acids are linked via an ester to the majority of the non-reducing termini of the D-arabinan. The mycolic acids are oriented perpendicular to the plane of the membrane and provide a truly special lipid barrier responsible for many of the physiological and disease-inducing aspects of M. tuberculosis. Intercalated within this environment are the phthiocerol dimycocerosates, cord factor or dimycolyltrehalose, sulfolipids, phosphatidylinositol mannosides and the related lipomannan and lipoarabinomannan, etc., agents responsible for much of the pathogenesis of tuberculosis. Interest in the biosynthesis of the cell-wall core, regarded, unlike the ancillary lipids, as essential to bacterial viability and integrity, is now driven by the pressing need for alternative drugs to counteract drug-resistant tuberculosis. In a manner analogous to the roles of lipid I and II in peptidglycan formation, synthesis of the entire arabinogalactan is initiated by transferring activated sugars to decaprenyl-phosphate, giving rise to the linker disaccharide, followed by stepwise elongation of the galactan, and the arabinan, apparently one sugar at a time. The genetics and enzymology of these polymerization events have not been well defined, nor have the final steps, namely the attachment of mycolic acids and ligation to peptidoglycan. However, what is known of the earlier events in cell-wall core synthesis has attracted interest in terms of new anti-tuberculosis drug development.
Keywords: Arabinogalactan, peptidoglycan, decaprenyl phosphate, mycolic acid, 2-C-methyl-D-erythritol 4-phosphate (MEP)
Current Topics in Medicinal Chemistry
Title: The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery.
Volume: 7 Issue: 5
Author(s): Patrick J. Brennan and Dean C. Crick
Affiliation:
Keywords: Arabinogalactan, peptidoglycan, decaprenyl phosphate, mycolic acid, 2-C-methyl-D-erythritol 4-phosphate (MEP)
Abstract: Present-day understanding of the architecture of the entire cell-wall of Mycobacterium tuberculosis amounts to a “core” template comprised of peptidoglycan with phosphodiester linkage, via a linker disaccharide, to a linear Dgalactofuran, to which, in turn, are attached several strands of a highly branched D-arabinofuran. The cell-wall mycolic acids are linked via an ester to the majority of the non-reducing termini of the D-arabinan. The mycolic acids are oriented perpendicular to the plane of the membrane and provide a truly special lipid barrier responsible for many of the physiological and disease-inducing aspects of M. tuberculosis. Intercalated within this environment are the phthiocerol dimycocerosates, cord factor or dimycolyltrehalose, sulfolipids, phosphatidylinositol mannosides and the related lipomannan and lipoarabinomannan, etc., agents responsible for much of the pathogenesis of tuberculosis. Interest in the biosynthesis of the cell-wall core, regarded, unlike the ancillary lipids, as essential to bacterial viability and integrity, is now driven by the pressing need for alternative drugs to counteract drug-resistant tuberculosis. In a manner analogous to the roles of lipid I and II in peptidglycan formation, synthesis of the entire arabinogalactan is initiated by transferring activated sugars to decaprenyl-phosphate, giving rise to the linker disaccharide, followed by stepwise elongation of the galactan, and the arabinan, apparently one sugar at a time. The genetics and enzymology of these polymerization events have not been well defined, nor have the final steps, namely the attachment of mycolic acids and ligation to peptidoglycan. However, what is known of the earlier events in cell-wall core synthesis has attracted interest in terms of new anti-tuberculosis drug development.
Export Options
About this article
Cite this article as:
Brennan J. Patrick and Crick C. Dean, The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery., Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059763
DOI https://dx.doi.org/10.2174/156802607780059763 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Development and Application of Virtual Screening in Drug Discovery: An Overview
Current Pharmaceutical Design New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Resistant Tuberculosis: the Latest Advancements of Second-line Antibiotic Inhalation Products
Current Pharmaceutical Design Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs
Current Biotechnology Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Epidemiology of Gout: Perspectives from the Past
Current Rheumatology Reviews Structure-Based Design of Inhibitors of the Crucial Cysteine Biosynthetic Pathway Enzyme O-Acetyl Serine Sulfhydrylase
Current Topics in Medicinal Chemistry Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery Subject Index To Volume 2
Current Respiratory Medicine Reviews Recent Progress in the Identification and Development of InhA Direct Inhibitors of Mycobacterium tuberculosis
Mini-Reviews in Medicinal Chemistry Microwave Assisted Preparation of New Dicoumarinyl Pyrazoline Derivatives as Antimicrobials
Current Microwave Chemistry Transition-State-Guided Drug Design for Treatment of Parasitic Neglected Tropical Diseases
Current Medicinal Chemistry Gender Disparity in Pediatric Diseases
Current Molecular Medicine Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology New Oxadiazole Derivatives: Synthesis and Appraisal of Their Potential as Antimicrobial Agents
Letters in Drug Design & Discovery